Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02621320
Other study ID # 2015-11
Secondary ID
Status Completed
Phase N/A
First received November 24, 2015
Last updated November 21, 2016
Start date November 2015
Est. completion date August 2016

Study information

Verified date November 2016
Source Swiss Paraplegic Centre Nottwil
Contact n/a
Is FDA regulated No
Health authority Switzerland: Ethikkommission
Study type Interventional

Clinical Trial Summary

There is a high prevalence of vitamin D deficiency in Switzerland. In indoor-athletes as well as wheelchair users, vitamin D deficiency occurs even more often. It is well established that vitamin D deficiency has a negative effect on health. However, vitamin D supplementation in individuals with a vitamin D deficiency has a positive effect on muscle performance. In recently published studies with able-bodied subjects, it has been shown that a normal vitamin D level (>75nmol/L) can only be achieved with a high-dose supplementation of vitamin D.

The aim of this study is to examine the effect of vitamin D supplementation on exercise performance in wheelchair athletes with vitamin D deficiency . All participants with a vitamin D deficiency are assigned to the intervention group and treated with 6000 IU of vitamin D3 daily over a period of 12 weeks. All participants who have a normal vitamin D level will receive placebo treatment (control group). The physical performance is measured three times at baseline, after six weeks and 12 weeks. The measurements include a Wingate and a dynamometer test.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date August 2016
Est. primary completion date July 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- swiss elite wheelchair athlete

- 18 to 60 years

- male, healthy

- at least 2x45min sports a week

Exclusion Criteria:

- participation in another study

- medication which influences performance

- respiratory and cardiovascular disease

- daily intake of >400IU Vitamin D

- parathyroid gland disease

- kidney insufficiency

- visit abroad below the 37th parallel latitude during study or shortly before

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Vitamin D
Vitamin D3 (Vi-De 3®. WILD) 6000IU daily over a period of 12 weeks.
Placebo
alcohol-based solution 1.3ml daily over a period of 12 weeks.

Locations

Country Name City State
Switzerland Swiss Paraplegic Centre Nottwil Lucerne

Sponsors (1)

Lead Sponsor Collaborator
Swiss Paraplegic Centre Nottwil

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Other Heart rate Peak heart rate measured during wingate test week 0, 1 day before they start supplementation No
Other Heart rate Peak heart rate measured during wingate test 12 weeks post supplementation No
Other blood lactate concentration before, during and after wingate test week 0, 1 day before they start supplementation No
Other blood lactate concentration before, during and after wingate test 12 weeks post supplementation No
Primary peak power peak power measured during wingate test delta change from pre to 12 weeks post supplementation No
Primary maximum torque maximum torque measured with dynamometer delta change from pre to 12 weeks post supplementation No
Secondary Vitamin D serum level measured with venous blood sample week 0, 1 day before they start supplementation Yes
Secondary Vitamin D serum level measured with venous blood sample 12 weeks post supplementation Yes
Secondary Count of injuries DASH questionaire 12 weeks post supplementation No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04244474 - Effect of Vitamin D Supplementation on Improvement of Pneumonic Children Phase 1/Phase 2
Recruiting NCT05459298 - ViDES Trial (Vitamin D Extra Supplementation) N/A
Completed NCT04476511 - The Efficacy and the Safety of Vitamin D3 30,000 IU for Loading Dose Schedules Phase 3
Suspended NCT03652987 - Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
Completed NCT03920150 - Vitamin D 24'000 IU for Oral Intermittent Supplementation Phase 3
Completed NCT03264625 - The Effects of Oral Vitamin D Supplementation on the Prevention of Peritoneal Dialysis-related Peritonitis Phase 2
Completed NCT04183257 - Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics Phase 4
Recruiting NCT05084248 - Vitamin D Deficiency in Adults Following a Major Burn Injury Phase 4
Completed NCT05506696 - Vitamin D Supplementation Study N/A
Completed NCT00092066 - A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227) Phase 3
Completed NCT03234218 - Vitamin D Levels in Liver Transplantation Recipients Prospective Observational Study
Completed NCT03203382 - Corneal Nerve Structure in Sjogren's
Completed NCT02714361 - A Study to Investigate the Effect of Vitamin D3 Supplementation on Iron Status in Iron Deficient Women N/A
Completed NCT02906319 - Vitamin D and HbA1c Levels in Diabetic Patients With CKD N/A
Completed NCT02118129 - Vitamin D Among Young Adults: an Intervention Study Using a Mobile 'App'. N/A
Completed NCT02187146 - The Effects of Serum Vitamin D and IVF Outcome N/A
Completed NCT02275650 - The Role of Narrowband Ultraviolet B Exposure in the Maintenance of Vitamin D Levels During Winter N/A
Not yet recruiting NCT01419821 - Vitamin D and Its Affect on Growth Rates and Bone Mineral Density Until Age 5 N/A
Completed NCT01741181 - Vitamin D Supplementation in Patients With Diabetes Mellitus Type 2 Phase 4
Completed NCT01651000 - Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency Phase 3